LyondellBasell expands Purell medical polymers to North America

LyondellBasell (LYB), one of the world’s largest producers of polymers and a leader in polyolefin technologies, today announced the expansion of its Purell portfolio in North America. For decades, Purell medical-grade polyolefins have been trusted by healthcare and pharmaceutical companies in Europe. With this expansion, LYB brings its proven service model, regulatory compliance and innovation-driven portfolio closer to customers across North America.

The Purell portfolio is designed for medical and healthcare applications, including syringes, ampoules, IV bottles, diagnostic housings, labware, inhalers and packaging. Backed by the LYB Purell Service Concept, customers benefit from:

• Stringent quality and traceability systems
• Dedicated manufacturing and logistics protocols
• Regulatory readiness, including USP and EU Pharmacopeia compliance and Drug Master Files (DMFs)
• Two-year notification of change (NOC), providing unmatched supply predictability

“Healthcare is a zero-fail environment,” said Sr. Director, Specialties & Perf. Products, Natalie Nichols. “With the Purell portfolio, we are helping customers achieve the performance the healthcare industry demands while leveraging our global expertise and local support.”

Simon Foster, industry marketing manager for healthcare, emphasized the importance of the expansion for customer collaboration: “Our customers need more than just reliable materials. They need a supplier who understands the unique pressures of the healthcare industry. Bringing Purell medical grade polymers to North America means we can work side by side with them, offering regulatory compliance, technical expertise and the supply confidence they need to innovate with assurance.”

With the North American expansion of the Purell portfolio, LYB reinforces its commitment to advancing healthcare innovation.

Note: The headline, insights, and image of this press release may have been refined by the ALCHEMPro staff; the rest of the content remains unchanged.

ALCHEMPro News Desk (HU)